Loading clinical trials...
Loading clinical trials...
EMPEROR: A Multicenter, Randomized, Double-blind, Sham-controlled, Parallel Group, Phase 3 Study Evaluating the Efficacy, Safety, and Tolerability of Zorevunersen (STK-001) in Patients With Dravet Syndrome
Conditions
Interventions
zorevunersen
Sham Comparator
Locations
61
United States
Phoenix Children's Hospital
Phoenix, Arizona, United States
Arkansas Children's Hospital
Little Rock, Arkansas, United States
Cedars Sinai Medical Center
Los Angeles, California, United States
Children's Hospital of Orange County
Orange, California, United States
USCF Medical Center
San Francisco, California, United States
Children's Hospital Colorado
Aurora, Colorado, United States
Start Date
June 4, 2025
Primary Completion Date
March 1, 2027
Completion Date
October 1, 2028
Last Updated
April 13, 2026
NCT05419492
NCT04462770
NCT06401538
NCT06598449
NCT06504511
NCT06118255
Lead Sponsor
Stoke Therapeutics, Inc
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions